Buzan R D, Dubovsky S L, Firestone D, Dal Pozzo E
Department of Psychiatry, University of Colorado School of Medicine, Denver 80262, USA.
J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):93-5. doi: 10.1176/jnp.10.1.93.
The cost, side effect profile, and required weekly blood draws associated with clozapine may dissuade some clinicians from prescribing this atypical neuroleptic to mentally retarded patients. All publications on clozapine use in mentally retarded patients are reviewed and the treatment of 10 such patients is described, bringing the total number of published cases to 84. Clozapine is efficacious and well tolerated in this population and should be considered for those patients with psychosis or bipolar illness who are intolerant of or unresponsive to other agents.
氯氮平的成本、副作用情况以及每周所需的血液检测，可能会使一些临床医生不愿为智障患者开具这种非典型抗精神病药物。本文回顾了所有关于氯氮平用于智障患者的出版物，并描述了对10名此类患者的治疗情况，使已发表病例总数达到84例。氯氮平在这一人群中疗效显著且耐受性良好，对于那些对其他药物不耐受或无反应的患有精神病或双相情感障碍的患者，应考虑使用氯氮平。
